Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Huntingtin (Huntington Disease Protein), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntingtin (Huntington Disease Protein) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Huntingtin (Huntington Disease Protein) Overview
  3. Therapeutics Development
  4. Pipeline Products for Huntingtin (Huntington Disease Protein) - Overview
  5. Pipeline Products for Huntingtin (Huntington Disease Protein) - Comparative Analysis
  6. Huntingtin (Huntington Disease Protein) - Therapeutics under Development by Companies
  7. Huntingtin (Huntington Disease Protein) - Therapeutics under Investigation by Universities/Institutes
  8. Huntingtin (Huntington Disease Protein) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Huntingtin (Huntington Disease Protein) - Products under Development by Companies
  13. Huntingtin (Huntington Disease Protein) - Products under Investigation by Universities/Institutes
  14. Huntingtin (Huntington Disease Protein) - Companies Involved in Therapeutics Development
  • AFFiRiS AG
  • Ionis Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • nLife Therapeutics, S.L.
  • reMYND NV
  • Sangamo BioSciences, Inc.
  • UniQure N.V.
  • Voyager Therapeutics, Inc.
  • Vybion, Inc.
  • WAVE Life Sciences Ltd.

For more information visit http://www.researchandmarkets.com/research/sd2cdb/huntingtin

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs